Centrexion Therapeutics changes its mind on initial public offering
The Boston-based company said it would not pursue a planned IPO, citing "market conditions." Nasdaq had agreed to its listing on Tuesday.
Centrexion’s $67M Series D round to fund Phase 3 pain studies
Despite being just four years old, Centrexion, which just raised $67 million, is building a significant pipeline of non-opioid, non-steroidal pain medications.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Centrexion nabs three non-opioid pain drugs from Boehringer Ingelheim
Boehringer Ingelheim offloaded the drugs, it said in a statement. because it's shifting away from pain medications to focus on CNS diseases like Alzheimer's, schizophrenia and depression.